Investigating the neuroprotective effect of Copolymer-1 in acute primary angle closure - Interim report of a randomized placebo-controlled double-masked clinical trial

What Was Tested

The paper reports a study of Glatiramer Acetate, published as a randomized controlled trial.

To investigate the neuroprotective effect of Copolymer-1 (Cop-1) in patients with acute primary angle closure (APAC) in a randomized double-masked controlled trial.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

After initial medical management, APAC patients were randomized to receive either subcutaneous Cop-1 or placebo within 24 hr and at 1 week.

After laser peripheral iridotomy (LPI), subjects underwent serial visual field (VF) tests and retinal nerve fibre layer (RNFL) thickness measurements with spectral-domain optical coherence tomography.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Glatiramer Acetate group and the comparison group should start out alike.

As a double-blind Glatiramer Acetate study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Glatiramer Acetate could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Acute Disease, Disease Progression, Glatiramer Acetate, Glaucoma, Angle-Closure, Intraocular Pressure, Neuroprotective Agents and Retinal Ganglion Cells.

The authors tagged it with the keywords acute primary angle closure, copaxone, neuroprotection and randomized controlled trial.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glatiramer Acetate.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Acta ophthalmologica), a journal based in England.

More context: the Glatiramer Acetate compound page, all human trials.